Literature DB >> 11981321

Posttranslational protein modifications: new flavors in the menu of autoantigens.

Hester A Doyle1, Mark J Mamula.   

Abstract

Perhaps one of the most elusive areas of study in autoimmunity has been identifying the self-antigens that initially trigger the development of autoimmune responses. Recent work in this area has demonstrated that a number of biochemical modifications that arise in proteins after their translation induce autoimmune responses to otherwise ignored self-proteins. This article will describe those autoimmune diseases in which posttranslational modifications may play a role in initiation of disease, as well as identify how these modifications arise and contribute to the breakdown of immune tolerance. Lastly, we will address how posttranslational modifications in self-antigens affect current diagnostic techniques and the development of immunotherapies for autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981321     DOI: 10.1097/00002281-200205000-00009

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  27 in total

1.  Organellar proteomics reveals Golgi arginine dimethylation.

Authors:  Christine C Wu; Michael J MacCoss; Gonzalo Mardones; Claire Finnigan; Soren Mogelsvang; John R Yates; Kathryn E Howell
Journal:  Mol Biol Cell       Date:  2004-03-26       Impact factor: 4.138

2.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.

Authors:  Nirit Mor-Vaknin; Ferdinand Kappes; Amalie E Dick; Maureen Legendre; Catalina Damoc; Seagal Teitz-Tennenbaum; Roland Kwok; Elisa Ferrando-May; Barbara S Adams; David M Markovitz
Journal:  Arthritis Rheum       Date:  2011-02

Review 3.  The sentinel within: exploiting the immune system for cancer biomarkers.

Authors:  Karen S Anderson; Joshua LaBaer
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

4.  Identification of immunoglobulins that recognize 3-nitrotyrosine in patients with acute lung injury after major trauma.

Authors:  Leonor Thomson; Jason Christie; Caryn Vadseth; Paul N Lanken; Xiaoming Fu; Stanley L Hazen; Harry Ischiropoulos
Journal:  Am J Respir Cell Mol Biol       Date:  2006-10-05       Impact factor: 6.914

5.  Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids.

Authors:  Varun Gauba; Jan Grünewald; Vanessa Gorney; Lisa M Deaton; Mingchao Kang; Badry Bursulaya; Weijia Ou; Richard A Lerner; Christian Schmedt; Bernhard H Geierstanger; Peter G Schultz; Teresa Ramirez-Montagut
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

6.  HLA-dependent autoantibodies against post-translationally modified collagen type II in type 1 diabetes mellitus.

Authors:  R Strollo; P Rizzo; M Spoletini; R Landy; C Hughes; F Ponchel; N Napoli; A Palermo; R Buzzetti; P Pozzilli; A Nissim
Journal:  Diabetologia       Date:  2012-11-19       Impact factor: 10.122

Review 7.  A tale of two citrullines--structural and functional aspects of myelin basic protein deimination in health and disease.

Authors:  George Harauz; Abdiwahab A Musse
Journal:  Neurochem Res       Date:  2006-08-09       Impact factor: 3.996

8.  Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response.

Authors:  Danielle B Ulanet; Michael Torbenson; Chi V Dang; Livia Casciola-Rosen; Antony Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

9.  Identification of CLP36 as a tumor antigen that induces an antibody response in pancreatic cancer.

Authors:  Su-Hyung Hong
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

10.  Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis.

Authors:  Richard Vytásek; Liliana Sedová; Vladimír Vilím
Journal:  BMC Musculoskelet Disord       Date:  2010-05-03       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.